Swiss pharmaceutical giant Roche is injecting 710 billion won (approximately $484 million) into South Korea’s biopharma sector. This investment aims to attract high-profile international clinical trials and cultivate specialized research talent within the nation.
Roche solidified this commitment by signing a memorandum of understanding (MOU) with South Korea’s Ministry of Health and Welfare. The partnership is designed to bolster the core competitiveness of the local bio-healthcare industry by establishing a robust ecosystem for global clinical research and enhancing R&D capabilities for innovative medicines.
This collaboration aligns with the South Korean government’s strategic efforts to foster partnerships between domestic biotechs and global pharmaceutical leaders like AbbVie and Novo Nordisk. South Korea’s pharma market is on a steep growth trajectory, with projections reaching nearly $54 billion by 2032. Roche’s significant capital infusion is expected to act as a catalyst for the rapid growth and global expansion of the country’s promising bio-health firms.
Source: https://www.fiercebiotech.com/biotech/roche-pumps-480-million-south-korea-biopharma-industry